These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A clinical analysis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation].
    Author: Qin CJ, Liu LJ, Zhang ZM, Luo L, Lai YR, Li QC.
    Journal: Zhonghua Nei Ke Za Zhi; 2018 Jul 01; 57(7):483-486. PubMed ID: 29996265.
    Abstract:
    Objective: To analyze the outcome and the prognostic factors of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Methods: A total of 797 patients receiving HSCT were analyzed retrospectively. The prophylaxis regimen of HVOD in the First Affiliated Hospital of Guangxi Medical University consisted of low molecular weight heparin and lipoprostaglandin E1 (PGE1). Results: Fifty-nine patients (7.4%) developed HVOD at 3-49 days after HSCT (median 12 days). Age younger than 15 years at transplant(HR= 6.47, P<0.001), busulphan conditioning (HR=6.40, P<0.001), thalassemia major (HR=6.35, P<0.001), allogeneic transplantation (HR=7.74, P=0.005) were univariate risk factors for HVOD. Multivariate analyses suggested that thalassemia major and busulphan conditioning were independently correlated with the development of HVOD. Conclusion: Thalassemia major and busulphan conditioning are independent risk factors for HVOD after HSCT. 目的： 探讨造血干细胞移植后肝静脉闭塞病（HVOD）的危险因素。 方法： 回顾分析广西医科大学第一附属医院2004年6月到2017年3月接受造血干细胞移植的797例患者资料，患者均采用低分子肝素钙联合前列地尔脂质微球体预防HVOD。 结果： 797例患者中59例发生HVOD，总发生率为7.4%，中位发生时间为移植后12 (3~49) d。单因素分析显示，年龄<15岁、重型地中海贫血患者、异基因移植、预处理方案包含马利兰是影响HVOD发生的因素。多因素分析结果显示，重型地中海贫血患者和预处理方案包含马利兰是影响HVOD发生的独立危险因素。 结论： 重型地中海贫血患者和预处理采用马利兰是发生HVOD的高危因素。.
    [Abstract] [Full Text] [Related] [New Search]